EPIFIX® / AmnioFix®
Diabetic Foot Ulcers (DFU)
Key Facts
About MiMedx Group
MiMedx Group leverages its proprietary PURION® processing platform to develop and commercialize regenerative tissue products derived from human placental tissue. The company's primary focus is on the advanced wound care and surgical recovery markets, with a portfolio of products designed to address unmet needs in tissue repair. As a commercial-stage entity, MiMedx has established a sales and distribution network while continuing to advance its clinical pipeline. The company's strategic direction involves expanding clinical evidence for its products and exploring new therapeutic applications for its placental tissue platform.
View full company profileAbout MiMedx Group
MiMedx Group leverages its proprietary PURION® processing platform to develop and commercialize regenerative tissue products derived from human placental tissue. The company's primary focus is on the advanced wound care and surgical recovery markets, with a portfolio of products designed to address unmet needs in tissue repair. As a commercial-stage entity, MiMedx has established a sales and distribution network while continuing to advance its clinical pipeline. The company's strategic direction involves expanding clinical evidence for its products and exploring new therapeutic applications for its placental tissue platform.
View full company profile